PORTEC-4a Newsletter No 5 2 February 2021

The 400th patient has been included in the PORTEC-4a trial!

This 'milestone' of the PORTEC-4a trial was reached on the 6th of January. Since the last newsletter, which was sent in April 2020, a total of 93 patients were included in the trial. So even during the COVID-19 pandemic accrual has remained satisfactory. Currently a total of 416 patients have been recruited. The top month in 2020 was November, with 15 included patients.

Please see the table and graphs below showing the accrual by month and by site, respectively.





Center	control arm	molecular profile	Total
Amsterdam UMC	7	17	24
Catharina Hospital	5	15	20
Erasmus Medical Center	6	11	17
Evang. Klinik Essen-Mitte (D)	1	2	3
Haaglanden Medical Center	4	6	10
Isala Hospital	4	2	6
Kaiserswerther Diakonie Dusseldorf (D)	1	1	2
Leiden UMC	20	45	65
Maastro Clinic	21	45	66
NKI/AvL	6	12	18
Radboud UMC	3	3	6
Radiotherapy Group Arnhem/Deventer	15	47	62
Radiotherapy Institute Friesland	6	13	19
Rotkreuzklinikum München (D)	1	4	5
St Luke's Hospital (Irl)	1	2	3
Tuebingen University Hospital (D)	7	14	21
UMC Groningen	4	7	11
UMC Utrecht	1	4	5
Universitätsklinikum Luebeck (D)	1	3	4
University Hospital Gent (B)	2	3	5
University Hospital Prague (Cz)	7	8	15
Verbeeten Institute	13	11	24
Zeeuws Radiotherapy Institute	2	3	5
Total	138	278	416

New international sites

We are very pleased to report that new international sites were activated for participation in the PORTEC-4a trial in the year 2020 - 2021.

Germany – three new German sites were activated

- the Universitätsklinikum Schleswig-Holstein, Campus Lubeck activated on the 19th of May
- the Kaiserswerther Diakonie Dusseldorf and Cologne, activated on the 22nd of July
- the University Hospital in Heidelberg, activated on the 3rd of December.

The Austrian Medical University of Vienna was activated on the 12th of November. The French GINECO group with nine potential sites has been activated on the 19th of January 2021. Site activations are

still to follow. The determination of the integrated-molecular profile and trial coordination will be done at Institut Gustave Roussy, Paris.

The Swiss sites Bern and Lucerne and the German site Berlin are currently in the final preparatory phase.

We would like to thank all local PIs and their teams for all the work they have done for activation of the trial in their centers.

PORTEC-4a during the COVID-19 pandemic
Unfortunately all participating sites, teams and patients are still suffering from the COVID-19 pandemic. We are very pleased with the resilience of all participating sites during these challenging times. Only in a few cases minor or major protocol deviations were needed, most often follow-up by telephone or some delay in start of treatment. Please make sure that in case of a deviation (either minor or major) of the protocol, the PORTEC-4a study team is well informed, preferably by e-mail (portec@iknl.nl, c.l.creutzberg@lumc.nl or a.v.m.van_den_heerik@lumc.nl). Also in the case of any uncertainties or questions, please do not hesitate to contact the PORTEC-4a study team.

Validation of pathology labs
Last year it was planned to validate several regional labs in the Netherlands for the integrated molecular profile. However, due to COVID-19 it was unavoidable to delay this process. Very recently we have been able to restart the validation process. Currently the pathology labs of UMC Amsterdam - AMC and the UMC Maastricht are in the process of being validated. We aim to have the majority of large regional pathology labs in the Netherlands validated before the end of the PORTEC-4a trial.

Currently the international pathology laboratories which have been validated for determination of the profile are those in Tübingen, Dublin, Prague, Austria and France.

Data management and monitoring
Karen Verhoeven-Adema is the PORTEC-4a central data manager and coordinator at the Trial Office, please email her at portec@iknl.nl
All up-to-date trial documents (i.e. the latest version of the protocol, pathology CRFs) can be found on the PORTEC-4a website: www.msbi.nl/portec4

Central monitoring and data checks of CRF entered via the TRIAS system are done on a 3-monthly basis and queries sent accordingly; please make sure all queries are dealt with in a timely fashion.

On-site monitoring in the Netherlands has been largely replaced by virtual monitoring by our monitor Dorien Berends-vd Meer, which has restarted since last November. In the previous years it was shown that monitoring remains an useful instrument and enhances the quality of the PORTEC-4a trial.
New is that thanks to the virtual monitoring we will be able to start annual virtual onsite monitoring for the international sites as well in the upcoming year.

SAE – No new SAE has been reported since 2019.

DSMB
The Data and Safety Monitoring Board have had their annual teleconference on 17 November 2020, and were pleased with the increased accrual and overall conduct of the trial. Their report has been sent to the Ethics committee and to the local PIs. The next DSMB teleconference will be held in November 2021.

PORTEC-4a: Meetings, presentations and publications
Last year, no PORTEC-4a investigator meetings have been planned due to the transition to virtual GCIG meetings without satellites. However, presentations on the background and design and updates about the PORTEC-4a trial are given during international presentations given by the PORTEC-4a study team.

Overview of PORTEC-4a related publications:
- A Dutch clinical trial article has been published in NTVO in 2017
- Results of the pilot phase: Wortman et al, Gynecol Oncol 2018 151(1): 69-75.
- The design of the PORTEC-4a trial: Van den Heerik et al, Int J Gynecol Cancer, 2020 30 (12): 2002-2007
- Dummy run and QA: Wortman et al, Radiother Oncol, 2021 155: 160 – 166.